Abstract
Metastasis is a complex process that propagates cells from the primary or initial site of the cancer occurrence to distant parts of the body. Cancer cells break from the cancer site and circulate through the bloodstream or lymph vessels, allowing them to reach nearly all parts of the body. These circulating tumour cells (CTCs) contain specialized metastasisinitiating cells (MICs) that reside in the biological heterogeneous primary tumour. Researchers have hypothesized that metastasis of renal cell carcinoma is initiated by circulation of MICs in patients’ blood and bone marrow. Based on the cancer stem/progenitor cell concept of carcinogenesis, understanding the molecular phenotypes of metastasis-initiating cells (MICs) in renal cancer could play a vital role in developing strategies for therapeutic interventions in renal cancer. Existence of MICs among CTCs in renal carcinoma has not been proven in large scale. However, some studies have reported that specialized markers are found on the surface of circulating cells from the primary tumour. In mice, MICs have been isolated from CTCs using such markers, which have then been transplanted into xenograft model to show whether they give rise to metastasis in different organs. Considering these findings, in this review we have attempted to summarize the studies connected with MICs and their gene expression profiles that are responsible for metastasis in renal cancer.
Keywords: Circulating tumour cells, metastasis-initiating cells, renal cell carcinoma, tumour-initiating cells.
Current Signal Transduction Therapy
Title:Metastasis-Initiating Cells in Renal Cancer
Volume: 8 Issue: 3
Author(s): Mohammed I. Khan, Anna M. Czarnecka, Renata Duchnowska, Wojciech Kukwa and Cezary Szczylik
Affiliation:
Keywords: Circulating tumour cells, metastasis-initiating cells, renal cell carcinoma, tumour-initiating cells.
Abstract: Metastasis is a complex process that propagates cells from the primary or initial site of the cancer occurrence to distant parts of the body. Cancer cells break from the cancer site and circulate through the bloodstream or lymph vessels, allowing them to reach nearly all parts of the body. These circulating tumour cells (CTCs) contain specialized metastasisinitiating cells (MICs) that reside in the biological heterogeneous primary tumour. Researchers have hypothesized that metastasis of renal cell carcinoma is initiated by circulation of MICs in patients’ blood and bone marrow. Based on the cancer stem/progenitor cell concept of carcinogenesis, understanding the molecular phenotypes of metastasis-initiating cells (MICs) in renal cancer could play a vital role in developing strategies for therapeutic interventions in renal cancer. Existence of MICs among CTCs in renal carcinoma has not been proven in large scale. However, some studies have reported that specialized markers are found on the surface of circulating cells from the primary tumour. In mice, MICs have been isolated from CTCs using such markers, which have then been transplanted into xenograft model to show whether they give rise to metastasis in different organs. Considering these findings, in this review we have attempted to summarize the studies connected with MICs and their gene expression profiles that are responsible for metastasis in renal cancer.
Export Options
About this article
Cite this article as:
Khan I. Mohammed, Czarnecka M. Anna, Duchnowska Renata, Kukwa Wojciech and Szczylik Cezary, Metastasis-Initiating Cells in Renal Cancer, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206222431
DOI https://dx.doi.org/10.2174/1574362409666140206222431 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry 4-aryl/heteroaryl-4H-fused Pyrans as Anti-proliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Protein-based Strategies of Molecular Therapy in Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry The Role of Culture and Ethnicity in the Adjustment to Gynecological Cancer
Current Women`s Health Reviews Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery PEGylated Nanoliposomes Potentiated Oral Combination Therapy for Effective Cancer Treatment
Current Drug Delivery Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Editorial [Hot Topic:Recent Advances in Developmental and Reproductive Toxicology (Executive Editor: Gian Mario Tiboni )]
Current Pharmaceutical Design FDG-PET/CT Imaging of Infected Bones and Prosthetic Joints
Current Molecular Imaging (Discontinued) The Role of Mesothelin in Tumor Progression and Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therapy
Current Medicinal Chemistry Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition Effects of Polymorphisms of the CYP450 Enzyme Genes on Estrogen Status and the Risk for Osteoporosis
Current Pharmacogenomics Concise Synthesis of 1,1-Diarylvinyl Sulfones and Investigations on their Antiproliferative Activity <i>via</i> Tubulin Inhibition
Anti-Cancer Agents in Medicinal Chemistry Molecular Field Analysis (MFA) and Other QSAR Techniques in Development of Phosphatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds
Current Topics in Medicinal Chemistry A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets